概要
目的
利用胶体金快速检测试剂盒测定恢复期患者血浆中 IgG/IgM 的抗体滴度, 回顾性分析新型冠状病毒肺炎 (COVID-19) 患者临床特征抗体效价变化特点, 以及两者间的相关性.
创新点
利用胶体金检测试剂盒检测恢复期血浆抗体滴度, 结合重症及危重症患者病例特点及实验室检测指标分析血浆抗体效价变化规律, 及其临床特征的关系, 为临床重症及危重症患者诊治以及筛选恢复期血浆供者提供参考依据.
方法
收集 293 份来自 COVID-19 康复者随访过程中的血液标本, 取血浆原液, 用生理盐水按不同比例 (1:80、 1:160、 1:320 和 1:640) 稀释后进行胶体金试纸法 IgG/IgM 抗体检测, 并记录相应患者检验指标水平. 通过电子病历系统检索回顾性分析温州市第六人民医院截至 2020 年 2 月 24 日确诊的 COVID-19 患者的流行病学特征和临床信息. 通过线性回归分析两变量之间的相关性, P<0.05 时具有统计学意义.
结论
症状出现 4∼6 周时, COVID-19 患者恢复期血浆 IgG 滴度水平可达到 1:320∼1:640 或者更高水平. 此时部分患者的血浆 IgM 仍为阳性. COVID-19 患者恢复期血浆 IgM 抗体滴度检测结果显示男性较女性高. 本研究中危重症患者均需要无创通气来维持生命, 且重症和极危重症患者均易发生水、 电解质紊乱. COVID-19 发病早期发生凝血功能障碍及炎症, 与恢复期血浆中 IgG 和 IgM 的抗体滴度水平存在一定相关性.
Article PDF
References
Arabi Y, Balkhy H, Hajeer AH, et al., 2015. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springer-Plus, 4:709. https://doi.org/10.1186/s40064-015-1490-9
Berry M, Gamieldien J, Fielding BC, 2015. Identification of new respiratory viruses in the new millennium. Viruses, 7(3):996–1019. https://doi.org/10.3390/v7030996
Chan JFW, Yao YF, Yeung ML, et al., 2015. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis, 212(12):1904–1913. https://doi.org/10.1093/infdis/jiv392
Chen L, Xiong J, Bao L, et al., 2020. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis, 20(4):398–400. https://doi.org/10.1016/S1473-3099(20)30141-9
Huang DQ, Chen R, Wang YQ, et al., 2019. Development of a colloidal gold-based immunochromatographic strip for rapid detection of Rice stripe virus. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(4):343–354. https://doi.org/10.1631/jzus.B1800563
Lee YL, Liao CH, Liu PY, et al., 2020. Dynamics of anti-SARS-CoV-2 IgM and IgG antibodies among COVID-19 patients. J Infect, 81(2):E55–E58. https://doi.org/10.1016/j.jinf.2020.04.019
Li L, Tong XL, Chen HW, et al., 2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion, 60(8):1765–1772. https://doi.org/10.1111/trf.15918
Liu YL, Sun WW, Li J, et al., 2020. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv, preprint. https://doi.org/10.1101/2020.02.17.20024166
Long QX, Liu BZ, Deng HJ, et al., 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med, 26(6):845–848. https://doi.org/10.1038/s41591-020-0897-1
Marano G, Vaglio S, Pupella S, et al., 2016. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus, 14(2):152–157. https://doi.org/10.2450/2015.0131-15
Samanta D, Willis E, 2016. Focal seizure associated with human parvovirus B19 infection in a non-encephalopathic child. World J Pediatr, 12(1):118–120. https://doi.org/10.1007/s12519-015-0060-0
Shi Y, Wang G, Cai XP, et al., 2020. An overview of COVID-19. J Zhejiang Univ Sci B (Biomed & Biotechnol), 21(5):343–360. https://doi.org/10.1631/jzus.B2000083
Singh L, Mishra S, Prasanna S, et al., 2015. Seroprevalence of TORCH infections in antenatal and HIV positive patient populations. Med J Armed Forces India, 71(2):135–138. https://doi.org/10.1016/j.mjafi.2014.12.009
To KKW, Hung IFN, Chan JFW, et al., 2013. From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis, 5(S2):S103–S108. https://doi.org/10.3978/j.issn.2072-1439.2013.06.02
WHO, 2020. Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
Zhang LB, Pang RR, Xue X, et al., 2020. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging, 12(8):6536–6542. https://doi.org/10.18632/aging.103102
Acknowledgments
We thank Dr. Ke HAO (Research Center of Blood Transfusion Medicine, Ministry of Education Key Laboratory of Laboratory Medicine, Department of Blood Transfusion, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China) for revising manuscript and giving good suggestions.
Author information
Authors and Affiliations
Contributions
Wei-ling XIANG and Jing-jing CHENG conducted the testing. Lian-peng WU, Fei-hang GE, Dong CHEN, and Wei ZHANG collected the clinical data. Bing-yu CHEN, Wen-xin LI, and Dan-ying QIU performed the statistics and analyses of the data. Wei-ling XIANG wrote the first draft of the manuscript. Dong CHEN and Zhen WANG designed the study. All authors have read and approved the final manuscript and, therefore, have full access to all of the data in the study and take responsibility for the integrity and accuracy of the data.
Corresponding authors
Additional information
Compliance with ethics guidelines
Wei-ling XIANG, Jing-jing CHENG, Lian-peng WU, Bing-yu CHEN, Wen-xin LI, Dan-ying QIU, Wei ZHANG, Fei-hang GE, Dong CHEN, and Zhen WANG declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.
List of electronic supplementary materials
Fig. S1 Correlation between IgG/IgM titer and different laboratory indexes
Project supported by the Zhejiang Medical and Health Science and Technology Project (Nos. 2017KY005, 2019KY017, and 2018KY868), the Key Projects Jointly Constructed by the Ministry and the Province of Zhejiang Medical and Health Science and Technology Project (No. WKJ-ZJ-2019), and the Key and Major Projects of Traditional Chinese Medicine Scientific Research Foundation of Zhejiang Province (Nos. 2019ZZ001 and 2018ZY001), China
Electronic supplementary materials
Rights and permissions
About this article
Cite this article
Xiang, Wl., Cheng, Jj., Wu, Lp. et al. Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China. J. Zhejiang Univ. Sci. B 21, 955–960 (2020). https://doi.org/10.1631/jzus.B2000593
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2000593